There were no cases of fatal outcomes among the studied cohort of HIV/TB patients with TB-IRIS, and after 6 months of therapy, on the whole, this group of patients did not show a significant difference in CD4+ cell growth and a decrease in viral load compared to the group of HIV/TB patients without TB-IRIS. This evidence concerns the gene CD4 and tuberculosis.